An ISO 9001:2008 & GMP certified company  | info@arlakbiotech.com  |  +91-9803023099, 7696263636  |  1800-121-6263 (Toll Free) 

WYDASE-D TAB


COMPOSITION:

SERATIOPEPTIDASE 10MG & DICLOFENAC 50MG

PHARMACOLOGY

PHARMACODYNAMICS

Diclofenac exerts potent anti-inflammatory, anti-pyretic and analgesic activity by inhibition of cyclo-oxygenase pathway (COX) and thus inhibits biosynthesis of prostaglandin and other pro-inflammatory mediators of pain pathway.
Serratiopeptidase, a bacterial peptide-cleaving enzyme obtained from Serratia marcescens. Serratiopeptidase is also a potent anti-inflammatory agent that exerts fibrinolytic and anti-edematic property. The therapeutic enzyme reduce inflammation and swelling in the affected area.

PHARMACOKINETICS:

ABSORPTION:

Diclofenac sodium + Serratiopeptidase is rapidly absorbed in the GIT. However, the absorption rate is very slow in enteric-coated formulations.

DISTRIBUTION:

The drug can enter breast milk and synovial fluid after distribution. The plasma protein binding capability of Diclofenac sodium + Serratiopeptidase is about 99%.

METABOLISM:

Diclofenac sodium + Serratiopeptidase is extensively metabolized in the liver and converted into active metabolites.

EXCRETION:

The drug is extensively excreted in urine as glucuronide and sulfate conjugates. The rest of the elimination is via the bile. The terminal half-life of Diclofenac sodium + Serratiopeptidase is about 1-2 hours.

Contact Us
close slider